Table 1 Patient data

From: Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes

Beadchip

aCases

Controls

Total

n

Male (%)

Female (%)

Age, mean (S.D.)

n

Male (%)

Female (%)

Age, mean (S.D.)

n

Age, mean (S.D.)

Illumina 660

1193

55%

45%

66.7 (8.50)

664

39%

61%

76.5 (8.50)

1857

70.0 (9.73)

Illumina OEE

294

51%

49%

65.6 (7.50)

3009

36%

64%

75.0 (8.70)

3303

74.0 (9.05)

Illumina GSA

1030

56%

44%

65.7 (8.10)

1226

40%

60%

73.0 (7.96)

2256

69.8 (8.86)

Illumina GSA/OEE

130

56%

44%

74.0 (17.9)

632

50%

50%

84.0 (11.51)

762

82.0 (13.7)

Illumina OEE, batch 2

132

52%

48%

53

45%

55%

185

Total

2779

55%

45%

66.5 (9.11)

5584

40%

60%

75.8 (9.42)

8363

72.8 (10.31)

  1. GSA global screening array, OEE Infinium Omni, SD standard deviation.
  2. a125 PSP cases were not autopsy confirmed, age is years alive.